

Organized By:



Implications of (a) Myriad Case on patent eligibility of genes in U.S.; (b) Compulsory Licensing on Pharmaceutical Industry in India

Where : Board Room , Venture Center, NCL Innovation park

Time : 2pm to 3pm

Abstract – The recent judgment from the Supreme Court of U.S. has significantly altered the patent eligibility of genes in US. The human genes are no more patentable in US. This judgment is expected to impact the way Inventions are claimed and the scope of monopoly provided by USPTO. However, will this judgment adversely affect innovation in the biotech Industry?



Mr. Ravi Bhola

Patent Attorney

Qualification:

M.Sc. (Biotechnology) – Jawaharlal Nehru University, Delhi
LL.B

Practice Focus:

Ravi is a Patent Attorney and heads the Bangalore Office of the Firm. He has handled filing and prosecution of Patent Applications for clients in diverse areas of technology. He also has vast experience and expertise in the handling of design applications and issues related thereto.

Apart from the above, Ravi regularly renders opinions on patent and design issues ranging from licensing, assignment, pre- and post-grant oppositions, freedom to operate, technology landscaping, due diligence, IP portfolio building strategy, patent pooling and assists clients in negotiations and enforcement of patent rights. He represents several multinational and domestic corporations on a variety of issues and works very closely with start-ups.

Prior to joining the firm, Ravi worked with a well-known multinational biotechnology corporation